<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04398524</url>
  </required_header>
  <id_info>
    <org_study_id>ISA101b-OPC-03-19</org_study_id>
    <nct_id>NCT04398524</nct_id>
  </id_info>
  <brief_title>A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC</brief_title>
  <official_title>A Phase II Study of Cemiplimab, an Anti-PD-1 Monoclonal Antibody, and ISA101b Vaccine in Patients With Recurrent/Metastatic HPV16 Positive Oropharyngeal Cancer Who Have Experienced Disease Progression With Prior Anti-PD-1 Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ISA Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ISA Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be an open-label, phase 2 study in which subjects will receive ISA101b and&#xD;
      cemiplimab.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will assess the ability of ISA101b plus cemiplimab to improve Overall Response&#xD;
      Rate in subjects who have progressed on prior anti-PD-1 therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate based on radiographic response</measure>
    <time_frame>20-25 monhts</time_frame>
    <description>Measured by RECIST version 1.1.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Squamous Cell Carcinoma of the Oropharynx</condition>
  <arm_group>
    <arm_group_label>single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ISA101b 3 times plus cemiplimab every 3 weeks for up to 24 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISA101B</intervention_name>
    <description>ISA101b 3 times plus cemiplimab every 3 weeks for up to 24 months</description>
    <arm_group_label>single arm</arm_group_label>
    <other_name>Cemiplimab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women ≥ 18 years of age.&#xD;
&#xD;
          -  Provide informed consent signed by study patient or legally acceptable representative.&#xD;
&#xD;
          -  Willing and able to comply with site visits and study-related procedures and&#xD;
             requirements.&#xD;
&#xD;
          -  Histologically confirmed recurrent or metastatic HPV16 positive OPC. Patients with&#xD;
             squamous cell carcinoma of occult primary site, presenting with lymph node(s) limited&#xD;
             only to the neck, are also eligible. Patients should have HPV16 positivity confirmed&#xD;
             before being considered a candidate for this study.&#xD;
&#xD;
          -  HPV16 positive disease as determined by a specified central reference laboratory&#xD;
             investigational use only assay.&#xD;
&#xD;
          -  Patients who have received a minimum of 4 doses of pembrolizumab or nivolumab or&#xD;
             equivalent anti-PD-1 antibody with or without chemotherapy for 1st or 2nd line&#xD;
             metastatic HPV16 positive OPC. The last dose of anti-PD-1 must have been no more than&#xD;
             6 months prior to the first dose of study drug. Progressive disease (PD) must have&#xD;
             been diagnosed during or after anti-PD-1 therapy (but not longer than 6 months after&#xD;
             the last dose).&#xD;
&#xD;
          -  At least one measurable lesion by CT or MRI per RECIST version 1.1 criteria. Target&#xD;
             lesions may be located in a previously irradiated field if there is documented disease&#xD;
             progression in that site.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status of 0 or 1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Major surgery within 14 days of first administration of enrollment.&#xD;
&#xD;
          -  Radiation therapy after progression on prior anti-PD-1 antibody.&#xD;
&#xD;
          -  Any intervening anti-cancer therapy since last dose of anti-PD-1 including induction&#xD;
             chemotherapy.&#xD;
&#xD;
          -  Patients who, after progressing on anti-PD-1, required subsequent chemotherapy within&#xD;
             the last 4 weeks prior to enrollment in order to control disease.&#xD;
&#xD;
          -  Patients who have permanently discontinued anti-cancer immune modulating therapies due&#xD;
             to drug-related toxicity.&#xD;
&#xD;
          -  Ongoing or recent (within 5 years) evidence of significant autoimmune disease that&#xD;
             required treatment with systemic immunosuppressive treatments. The following are not&#xD;
             exclusionary: vitiligo, childhood asthma that has resolved, endocrinopathies (such as&#xD;
             hypothyroidism or type 1 diabetes) that require only hormone replacement, or psoriasis&#xD;
             that does not require systemic treatment.&#xD;
&#xD;
          -  Untreated or active primary brain tumor, central nervous system (CNS) metastases,&#xD;
             leptomeningeal disease or spinal cord compression.&#xD;
&#xD;
          -  Encephalitis, meningitis, organic brain disease (e.g. Parkinson's disease) or&#xD;
             uncontrolled seizures in the year prior to first dose of study therapy.&#xD;
&#xD;
          -  Known history of, or any evidence of interstitial lung disease, or active,&#xD;
             non-infectious pneumonitis (in the past 5 years). A history of radiation pneumonitis&#xD;
             in the radiation field is permitted.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erminia Massarelli, MD</last_name>
      <phone>626-256-4673</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Douglas Adkins, MD</last_name>
      <phone>314-747-8475</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathew Taylor, MD</last_name>
      <phone>503-215-5696</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Texas M. D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bonnie Glisson, MD</last_name>
      <phone>713-792-6363</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Ghent</name>
      <address>
        <city>Ghent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvie Rottey, MD</last_name>
      <phone>+32(0)9 332 26 91</phone>
      <email>secretariaat.medischeoncologie@uzgent.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Liege</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brieuc Sautois, MD</last_name>
      <phone>+32 436 67 664</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinic of Oncology</name>
      <address>
        <city>Olomouc</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bohuslav Melichar, MD</last_name>
      <phone>00420 588 443 896</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of Radiation Oncology</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petra Holeckova, MD</last_name>
      <phone>00420-266 084 212</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU La Timone - La Timone Children's Hospital</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sébastien Salas, MD</last_name>
      <phone>+33(0)491385708</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jean Godinot Institute</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain Prevost, MD</last_name>
      <phone>+33 336504426</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Paul Strauss Center</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Borel, MD</last_name>
      <phone>0033388252485</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy Institute</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Even, MD</last_name>
      <phone>0033142115352</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Göttingen</name>
      <address>
        <city>Göttingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Chapuy, MD</last_name>
      <phone>0049 551 398943</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Licitra, MD</last_name>
      <phone>+39 (2) 2390 2150</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic of Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neus Baste, MD</last_name>
      <phone>+34 93 227 54 00</phone>
      <phone_ext>1493</phone_ext>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 18, 2020</study_first_submitted>
  <study_first_submitted_qc>May 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2020</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cemiplimab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

